Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
free free
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll The Pathogenesis and treatment of the valvulopathy of aortic stenosis: Beyond the SEAS Elmariah S; Mohler ER 3rdCurr Cardiol Rep 2010[Mar]; 12 (2): 125-32Fibrocalcific aortic stenosis (AS) results from an active process similar to atherosclerosis that involves basement membrane disruption, lipid deposition, inflammatory cell infiltration, and calcification. Consequently, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) have been extensively studied as potential therapeutic agents capable of slowing the progression of AS. However, two randomized trials, SALTIRE and the SEAS study, showed no benefit with statin therapy for AS. These results have shed doubt over the efficacy of statin therapy for AS, although their potential efficacy at early stages of aortic valve disease remains possible. In this article, we review the pathophysiology of fibrocalcific AS and discuss future directions for its nonsurgical management in the post-SEAS era.|Anticholesteremic Agents/therapeutic use[MESH]|Aortic Valve Stenosis/*drug therapy/epidemiology/pathology[MESH]|Aortic Valve/*pathology[MESH]|Arteriosclerosis/drug therapy/pathology[MESH]|Calcinosis/pathology[MESH]|Disease Progression[MESH]|Humans[MESH]|Hydroxymethylglutaryl-CoA Reductase Inhibitors/*therapeutic use[MESH]|Inflammation[MESH]|Risk Factors[MESH]|Transforming Growth Factor beta1[MESH]|Tumor Necrosis Factor-alpha[MESH]|United States/epidemiology[MESH] |